700561A new approach to point of assessment diagnosis of tuberculosisClosedGRD Proof of MarketInnovate UKWe have developed a novel device for the detection of TB which works in under 30 minutes; this is based on the recognition of unique molecules identical to components of the cell walls of mycobacteria by antibodies present in the serum of individuals with active TB. The target set by the World Health Organisation is for a field device that works rapidly and reliably and can be sold in high burden TB countries for around $ 5 - 10; our current device works in 15 minutes, does not require electricity or a specialist laboratory, and is expected to meet the cost criteria. We already have some patent protection applied for and need to confirm that we can obtain proper protection for a number of new disclosures. We need to validate our method in comparison with other devices currently available for use in a laboratory and which generally take several hours to provide a result, and to compare our method with the 'gold standard' of cell culture, that can take several weeks to provide a result. With this information to hand, we need to develop a detailed plan for the route to market, including the development of strict product specifications, quality control systems, and a strategy for achieving recognition by Government Agencies and bodies such as the WHO. If we can optimise the device, gain such recognition and meet the challenges of market penetration, a conservative estimate of the market need for such a device in high burden TB countries alone is some 50 million units per annum.